NCT03343093

Brief Summary

Development and evaluation of an online intervention addressing sexual functioning in gay and bisexual men (GBM) after prostate cancer treatment.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
403

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started Jan 2019

Longer than P75 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

October 30, 2017

Completed
18 days until next milestone

First Posted

Study publicly available on registry

November 17, 2017

Completed
1.1 years until next milestone

Study Start

First participant enrolled

January 1, 2019

Completed
2.7 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 15, 2021

Completed
1.8 years until next milestone

Study Completion

Last participant's last visit for all outcomes

June 20, 2023

Completed
10 months until next milestone

Results Posted

Study results publicly available

April 2, 2024

Completed
Last Updated

April 2, 2024

Status Verified

March 1, 2024

Enrollment Period

2.7 years

First QC Date

October 30, 2017

Results QC Date

October 23, 2023

Last Update Submit

March 5, 2024

Conditions

Keywords

Erectile Dysfunction

Outcome Measures

Primary Outcomes (4)

  • Urinary Function Scores

    The Urinary Function domain of the Expanded Prostate Cancer Index Composite (EPIC-50) scale was used to assess the frequency of urinary symptoms. Scores range from 0 to 100, with higher scores indicating less frequency of urinary symptoms.

    24 months

  • Sexual Functioning Scores

    The Sexual Functioning domain of the Expanded Prostate Cancer Index Composite (EPIC-50) scale was used to assess the frequency of sexual functioning symptoms. Scores range from 0 to 100, with higher scores indicating less frequency of sexual functioning symptoms.

    24 months

  • Intervention Acceptability

    Acceptability was measured by how much intervention group participants would recommend the intervention to a friend (if he had prostate cancer). This single Likert-type item has five response options from 1=strongly agree to 5= strongly disagree. Acceptability will be measured by adding those who answered 1=strongly agree or 2=agree on this item.

    3-month follow-up

  • Intervention Feasibility

    Feasibility will be measured by monitoring the number of intervention participants who could access the intervention webpage at least once within the first three months of the study.

    3-month follow-up

Study Arms (2)

Intervention Evaluation Control Group

EXPERIMENTAL

Surveys at 3 month intervals

Behavioral: Control

Intervention Evaluation Test Group

EXPERIMENTAL

We will evaluate the effects of an educational, tailored, online rehabilitation program addressing sexual and urinary outcomes after treatment by surveying at 3 month intervals

Behavioral: Restore Rehabilitation Program

Interventions

Multi-component, structured, biopsychosocial, online interactive program to address the sexual and urinary effects of prostate cancer treatment

Intervention Evaluation Test Group
ControlBEHAVIORAL

usual care, surveys every 3 months

Intervention Evaluation Control Group

Eligibility Criteria

Age18 Years+
Sexmale(Gender-based eligibility)
Gender Eligibility DetailsMale bodied persons at risk of prostate cancer
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Gay or Bisexual Men, defined as a biological adult male, who by self-report, has had sex with a man.
  • Treated for prostate cancer, defined as (i) having been diagnosed with prostate cancer and measured by being able to report a Prostate- Specific Antigen and Gleason score; and (ii) treated by radical prostatectomy, radiation or systemically.
  • Has recent problems with sexual and/or urinary function, by self-report. This is measured by a screener item(s) asking the enrollee to describe their current function (last 4 weeks) and validated by nurse interview.
  • Internet-using
  • Living in the US (including territories) as measured by valid US zip code
  • A unique, validated individual, as measured by our published de-duplication and cross-validation protocols,230-232 and confirmed by video or phone interview.

You may not qualify if:

  • No Nerve Sparing and Salvage therapy.
  • Medical contraindications as determined by investigators at screening
  • Heavy smoking: more than 10 cigarettes, cigars, e-cigarettes, snuff pipe or similar product on an average day (screened over last 7 days)
  • Heavy alcohol use: more than 4 drinks per day, on two or more days, last 7 days
  • Participation is limited to English speakers/readers since intervention materials and surveys are in English.
  • Cognitive impairment.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University of Minnesota Twin Cities Campus

Minneapolis, Minnesota, 55454, United States

Location

Related Publications (1)

  • Rosser BRS, Polter EJ, Chandiramani N, Cahill S, Wheldon CW, Konety BR, Ryan CJ, Haggart R, Kapoor A. Acceptability and Feasibility of Collecting Sexual Orientation and Expanded Gender Identity Data in Urology and Oncology Clinics. LGBT Health. 2021 Aug-Sep;8(6):420-426. doi: 10.1089/lgbt.2020.0256. Epub 2021 Aug 4.

MeSH Terms

Conditions

Prostatic NeoplasmsErectile Dysfunction

Condition Hierarchy (Ancestors)

Genital Neoplasms, MaleUrogenital NeoplasmsNeoplasms by SiteNeoplasmsGenital Diseases, MaleGenital DiseasesUrogenital DiseasesProstatic DiseasesMale Urogenital DiseasesSexual Dysfunction, PhysiologicalSexual Dysfunctions, PsychologicalMental Disorders

Results Point of Contact

Title
Gudrun Kilian
Organization
University of Minnesota

Study Officials

  • B. Simon Rosser, PhD

    University of Minnesota

    PRINCIPAL INVESTIGATOR

Publication Agreements

PI is Sponsor Employee
Yes

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
PARTICIPANT
Purpose
SUPPORTIVE CARE
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

October 30, 2017

First Posted

November 17, 2017

Study Start

January 1, 2019

Primary Completion

September 15, 2021

Study Completion

June 20, 2023

Last Updated

April 2, 2024

Results First Posted

April 2, 2024

Record last verified: 2024-03

Data Sharing

IPD Sharing
Will not share

Locations